Anupam Shukla is a finance content writer and an NISM-certified research analyst with over Seven years of trading experience. With a passion for the stock market, he simplifies complex financial concepts, making investing and trading easier for everyone. His expertise helps readers stay ahead in the ever-changing world of finance, empowering them to make smarter money moves.
If you have been tracking India's pharma space, you have probably noticed one theme coming up again and again: CDMO.
I have spent a good part of this year watching this sector closely, and what stands out to me is how a once-obscure outsourcing business has turned into one of the biggest growth stories on Dalal Street.
After COVID-19, global pharma majors started handing over more of their R&D and manufacturing work to specialist Indian companies, and that shift is still playing out.
In this blog, I will walk you through what the CDMO sector actually is, why it matters, and which CDMO stocks in India I think are worth keeping on your watchlist in 2026 - along with their latest prices, valuations and the risks you should weigh before investing.
CDMO stands for Contract Development and Manufacturing Organization.
In simple terms, these are pharma companies that handle the research, development and manufacturing for other drug companies.
Think of it this way: a large global pharma major invents a molecule, but instead of building its own plant to make it, it hands that job to a CDMO.
That saves the innovator both time and capital, and it is exactly why I believe this model has become so central to the industry.
Traditional Pharma vs CDMO: What is the difference?
Traditional pharma companies develop and market their own medicines under their own brand.
CDMO companies, on the other hand, only provide the service of developing, testing, and manufacturing products that another company has researched or patented.
You could call CDMO work "backend support" for the pharma industry.
But in my view, that backend has quietly become the backbone of global drug supply chains.
Why is CDMO important for Global Pharma companies?
Cost Efficiency: Outsourcing to a CDMO is usually cheaper than running in-house R&D and manufacturing.
Scalability: Production can be scaled up quickly to meet global demand.
Regulatory Compliance: Indian CDMOs meet major global standards like USFDA and WHO-GMP, which gives international clients confidence in quality.
How is India becoming a Global CDMO Hub?
India's combination of strong R&D talent, lower costs, an experienced workforce and consistent government support has allowed several domestic companies to win large global CDMO contracts.
I think this is the main reason CDMO pharma stocks in India have been growing so quickly, and why I see the sector as a genuine long-term growth story rather than a short-lived trend.
If you want to see how this plays out day to day, you can also check the share market today to track broader market movements and see how pharma and healthcare stocks are performing alongside CDMO names.
Top CDMO Stocks in India
Here is the list of leading CDMO companies in India that I have been following, based on their standing in the pharma sector and their global client relationships.
Prices and 52-week ranges below are live as of 12 October 2026.
(Prices and 52-week ranges as of 12 October 2026. Market capitalisation figures are approximate, derived from current price and the last reported outstanding share count.)
Here is a quick rundown of each company and what I think makes it stand out:
Divi's Laboratories logo1. Divi's Laboratories
Founded in 1990 by Dr. Murali Krishna Prasad Divi, this is the company I would point to first if you are new to the CDMO space.
It started out manufacturing Active Pharmaceutical Ingredients (APIs) and intermediates before becoming a leading CDMO.
Its production units in Hyderabad and Visakhapatnam meet global standards such as USFDA, WHO and EU-GMP, and the company has built long-term relationships with some of the biggest names in global pharma.
I see Divi's as the benchmark large-cap name in Indian CDMO.
CIPLA logo2. CIPLA
CIPLA was started in 1935 by Dr. K.A. Hamied and is one of the oldest, most trusted pharma names in India.
While it is best known for General Medicine, Respiratory, HIV and Oncology drugs, CIPLA has also expanded into Contract Development and Specialty Manufacturing.
This gives it a genuine foothold in the CDMO space alongside its core branded business.
Laurus Labs logo3. Laurus Labs
Founded in 2005, Laurus Labs has built a strong reputation in APIs, intermediates and formulations.
It has leaned into the CDMO model particularly in antiviral, cardiovascular and oncology segments.
Its in-house R&D and backward integration help it deliver faster for global clients, which is part of why I think it has emerged as one of the more dynamic names in this sector.
Gland Pharma logo4. Gland Pharma
Started in 1978, Gland Pharma specialises in injectable medicines and runs almost entirely on a B2B model, handling development through to manufacturing for global pharma clients.
Its focus areas - sterile injectables, oncology and complex formulations - plus its USFDA and EMA approvals make it one of the more execution-focused CDMO names on this list.
Syngene International logo5. Syngene International
Syngene, a Biocon Group subsidiary founded in 1993, focuses on Contract Research, Development and Manufacturing for clients including Bristol-Myers Squibb, GSK and Amgen.
Its work spans everything from early discovery to commercial-scale production, which is why I consider it a true end-to-end CDMO player rather than just a manufacturing-stage partner.
Piramal Pharma logo6. Piramal Pharma
Piramal Pharma's CDMO arm, Piramal Pharma Solutions, has built a presence across North America, Europe and Asia since the group's pharma roots in 1988.
It focuses on High Potency APIs, Injectable Drugs and Specialty Molecules, offering an end-to-end service from R&D through manufacturing and packaging, backed by USFDA and EMA-approved sites.
Concord Biotech logo7. Concord Biotech
Founded in 2000, Concord Biotech is one of the more interesting niche names I follow in this space.
It focuses on anti-infective, oncology and immuno-suppressant therapies, manufacturing both APIs and formulations.
Its ability to produce complex fermentation-based molecules at scale gives it a defensible niche among global clients.
Jubilant Pharmova logo8. Jubilant Pharmova
Jubilant Pharmova emerged from a 2020 demerger within the Jubilant Group.
Its CDMO operations run through Jubilant Biosys and Jubilant Chemsys, covering drug discovery and clinical development with a focus on oncology, neuroscience and metabolic disorders.
I would watch this one for its contract research pipeline rather than near-term earnings.
Aarti Drugs logo9. Aarti Drugs
Aarti Drugs, started in 1984, has a long-standing hold in API manufacturing and has increasingly moved into CDMO-style work in specialty chemicals and custom synthesis.
Its GMP-certified Maharashtra and Gujarat facilities and backward-integrated, cost-efficient production give it room to compete on pricing in this niche segment.
Dishman Carbogen Amcis, headquartered in Ahmedabad and started in 1983, specialises in custom synthesis and contract manufacturing, with facilities across India, Switzerland, France and China.
It focuses on Oncology, Cardiology and High Potency APIs for some of the world's largest pharma companies.
I would flag that its recent financial growth metrics have been weaker than peers - more on that below.
One name worth keeping on your radar even though it is outside this top-10 list is Akums Drugs and Pharmaceuticals, which has quickly built a reputation as one of the largest contract manufacturers for domestic pharma brands in India.
As of 12 October 2026 it trades around Rs. 754, with a 52-week range of Rs. 409 to Rs. 839.
I have not included it in the table above since its CDMO exposure leans more domestic-contract-manufacturing than export-led CDMO, but I think it is a name you should at least have on your watchlist.
Key Valuation and Growth Metrics
Rather than relying on older margin data, I pulled the latest live fundamentals for each stock.
This way you can see where valuations and recent profit growth actually stand today.
Company
ROCE (%)
P/E Ratio
P/B Ratio
Debt to Equity
Profit Growth YoY (%)
Divi's Laboratories
21.38
60.44
9.43
0.00
25.90
CIPLA
13.88
28.10
2.89
0.00
-43.12
Laurus Labs
14.95
72.29
10.19
0.45
71.23
Gland Pharma Ltd
17.11
21.52
2.59
0.00
22.76
Syngene International
9.41
51.55
3.34
0.05
-51.12
Piramal Pharma
10.77
25.89
2.22
0.13
-2.63
Concord Biotech
18.33
40.36
5.26
0.00
-21.11
Jubilant Pharmova
1.79
205.65
5.61
0.08
83.81
Aarti Drugs
11.64
17.23
2.08
0.35
-4.25
Dishman Carbogen Amcis
0.00
0.00
0.53
0.17
-1642.09
(Data live as of 12 October 2026.)
Negative profit-growth figures reflect a high-base or weak-quarter effect and should be read alongside multi-year trends rather than in isolation - this is exactly the kind of number I would dig into further before drawing conclusions.
In my view, the Indian CDMO sector has moved well beyond being a pharma supporting act - it has become its own growth story.
Here is why I think it deserves a place on your radar.
Global client base and currency diversification: Contracts from the US, Europe and Japan bring in dollar revenues, which helps diversify currency risk and strengthens the client base of these companies.
Sustainable business model and high margins: With a relatively low capex model focused on production and delivery, many CDMO companies post EBITDA margins of 25-35%, often ahead of traditional pharma peers.
Technology and innovation-led leadership: High-entry-barrier capabilities such as mRNA, ADCs, biologics and peptides are helping these companies lead rather than follow industry innovation.
FII/DII interest and valuation support: Continued institutional interest in names like Syngene and Concord Biotech tells me the market still has confidence in this sector's longer-term trajectory.
Key Risks in CDMO Sector Stocks
I would not want to paint this as a one-sided growth story.
The Indian CDMO sector carries real risks that you should weigh before investing.
High reliance on clients: Many CDMO companies depend heavily on a handful of global clients.
If a major contract is not renewed, earnings can take a direct hit - you can see this pattern in some of the profit-growth numbers in the table above.
USFDA and other regulatory risks: Regulators like the USFDA closely monitor supply chains and manufacturing quality.
A warning letter or certification issue can disrupt growth for quarters at a time.
High R&D costs, uncertain returns: Heavy R&D spending does not always translate into new contracts, which can compress margins and profits.
Currency fluctuation risk: Since a large share of revenue is dollar or euro denominated, a stronger rupee can eat into reported profits.
How to invest in CDMO Stocks?
If you are thinking about adding CDMO exposure to your portfolio, I would suggest starting with a clear understanding of how this industry actually makes money.
That is more useful than just chasing recent price moves.
Before you invest, it is worth thinking about how this sector fits into your own financial goals, time horizon and risk appetite.
Goal-based investment planning can help you evaluate sector bets like this one as part of a wider portfolio strategy, rather than investing purely on growth potential.
If you would rather build your CDMO exposure gradually instead of investing a lump sum, a stock SIP lets you invest a fixed amount in eligible stocks at regular intervals.
I find this a useful way to bring some discipline to long-term investing in a sector that can be volatile quarter to quarter.
Why is investing through Rupeezy beneficial?
If you are considering a growth sector like CDMO, I think Rupeezy is worth a look.
Here are a few features that have made investing easier for our users.
Zero AMC Charges: You can run your Demat account on Rupeezy without any Annual Maintenance Charge.
5x Margin Trading Facility (MTF): Rupeezy offers Margin Trading Facility up to 5 times.
So if you have Rs. 10,000, you can trade up to Rs. 50,000, all within SEBI's regulatory framework.
T+5 Intraweek Facility - without interest: Rupeezy also offers a T+5 intraweek facility, letting you hold a position for up to 5 days without paying interest.
I think this is particularly useful if you are a short-term trader looking to play CDMO stock momentum around results.
Conclusion
The way I see it, the CDMO sector has become a genuinely important part of India's pharma growth story, not just a side business.
India's position in the global supply chain, combined with long-term outsourcing trends, makes it a sector worth your attention.
Companies like Divi's Laboratories, Syngene International and Laurus Labs are leading the pack today.
But as the valuation and growth numbers above show, performance varies a lot from one name to the next - so I would encourage you to look past the headline growth story and dig into each company's own numbers before deciding where to put your money.
If you want to see how pharma compares with other industries, you can also explore stock market sectors to understand broader sectoral trends.
CDMO stands for Contract Development and Manufacturing Organization - a company that handles research, development and manufacturing of medicines on behalf of another pharma company.
Q2. Are CDMO stocks good for long-term investment?
I think the CDMO sector has strong long-term growth potential given rising global outsourcing demand.
But returns vary significantly by company, so I would not treat it as a uniform bet - check the fundamentals of each stock individually.
Q3. Which are the top CDMO companies in India?
Divi's Laboratories, Syngene International, Laurus Labs and Gland Pharma are generally considered among the top CDMO companies in India, alongside names like CIPLA, Piramal Pharma and Concord Biotech.
Q4. Is the CDMO sector growing in India?
Yes, the CDMO sector in India is growing steadily, driven by rising pharma exports and global outsourcing demand, though individual companies are seeing very different growth rates right now.
Q5. How is CDMO different from regular pharma companies?
CDMO companies manufacture medicines on behalf of other companies under contract, while regular pharma companies develop, manufacture and sell medicines under their own brand.
Anupam Shukla is a finance content writer and an NISM-certified research analyst with over Seven years of trading experience. With a passion for the stock market, he simplifies complex financial concepts, making investing and trading easier for everyone. His expertise helps readers stay ahead in the ever-changing world of finance, empowering them to make smarter money moves.
The content on this blog is for educational purposes only and should not be considered investment advice. While we strive for accuracy, some information may contain errors or delays in updates.
Mentions of stocks or investment products are solely for informational purposes and do not constitute recommendations. Investors should conduct their own research before making any decisions.
Investing in financial markets are subject to market risks, and past performance does not guarantee future results. It is advisable to consult a qualified financial professional, review official documents, and verify information independently before making investment decisions.
Want to invest in stocks?
Open Rupeezy account now. It is free and 100% secure.